Targeting the Cause or the Consequence: Drug Development Strategies Across the Disease Cascade in IgA Nephropathy

• Exploring IgA nephropathy pathophysiology and the “four-hit” cascade to differentiate upstream causes versus downstream disease consequences
• Comparing therapeutic strategies targeting mucosal immune drivers versus kidneylevel effects, highlighting emerging approaches across the disease cascade
• Demonstrating how early intervention at disease origin impacts biomarkers, proteinuria, and kidney function, alongside evolving endpoints and clinical data

Speakers:

Rowland Elwell

Executive Medical Director, Nephrology

Calliditas